STAT3 and cancer: Hence, adjunctive STAT3 inhibition can increase the efficacy of T cells and enhance their affinity and cytotoxic action against cancer cells in combination with conventional immunotherapeutic agents, such as pembrolizumab, nivolumab, and sintilimab, which are administered for gastric cancer treatment.